BioSyent Stock Forecast, Price & News

+0.10 (+1.31 %)
(As of 07/30/2021 11:58 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume950 shs
Average Volume7,810 shs
Market CapitalizationC$98.29 million
P/E Ratio25.16
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive RX News and Ratings via Email

Sign-up to receive the latest news and ratings for BioSyent and its competitors with MarketBeat's FREE daily newsletter.

BioSyent logo

About BioSyent

BioSyent Inc., a specialty pharmaceutical company, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX 150, an oral hematinic; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; and FeraMAX Pd Therapeutic 150 for the prevention and treatment of iron deficiency anemia. It also offers Cathejell, a product indicated for surface anesthesia and lubrication during various procedures, including cystoscopy, catheterization, endourethral operation, endoscopy, proctoscopy, rectoscopy, and tracheal intubation, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis; Aguettant System for pre-filled syringes that are used for various injectable medications in hospital and acute care settings; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; Proktis-M, a rectal suppository for the healing of the anus and rectum; and Cysview, an adjunct to white-light cystoscopy for the detection and management of non-muscle invasive papillary bladder cancer. In addition, it provides Combogesic for moderate acute pain and reduction of fever in adults; Protect-It, a non-chemical food-safe grain insecticide product used as a preventative treatment against insect infestations in stored grains; and Tibella, a hormone replacement therapy to treat vasomotor symptoms due to estrogen deficiency. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006 to reflect its forward focus on the pharmaceutical market. BioSyent Inc. was incorporated in 2006 and is headquartered in Mississauga, Canada.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.23 out of 5 stars

Analyst Opinion: 1.0Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

BioSyent (CVE:RX) Frequently Asked Questions

Is BioSyent a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioSyent in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" BioSyent stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RX, but not buy additional shares or sell existing shares.
View analyst ratings for BioSyent
or view top-rated stocks.

What stocks does MarketBeat like better than BioSyent?

Wall Street analysts have given BioSyent a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but BioSyent wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is BioSyent's next earnings date?

BioSyent is scheduled to release its next quarterly earnings announcement on Wednesday, August 25th 2021.
View our earnings forecast for BioSyent

How were BioSyent's earnings last quarter?

BioSyent Inc. (CVE:RX) posted its earnings results on Thursday, May, 27th. The company reported $0.13 earnings per share for the quarter, beating analysts' consensus estimates of $0.09 by $0.04. The firm had revenue of $7.42 million for the quarter, compared to analyst estimates of $6.10 million.
View BioSyent's earnings history

How has BioSyent's stock price been impacted by Coronavirus?

BioSyent's stock was trading at C$4.35 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, RX stock has increased by 78.2% and is now trading at C$7.75.
View which stocks have been most impacted by COVID-19

What price target have analysts set for RX?

2 brokerages have issued 12 month target prices for BioSyent's shares. Their forecasts range from C$7.50 to C$7.50. On average, they anticipate BioSyent's share price to reach C$7.50 in the next twelve months. This suggests that the stock has a possible downside of 3.2%.
View analysts' price targets for BioSyent
or view top-rated stocks among Wall Street analysts.

Who are BioSyent's key executives?

BioSyent's management team includes the following people:
  • Mr. René C. Goehrum, Chairman, CEO & Pres
  • Mr. Robert J. March, VP of Fin. & CFO
  • Mr. Joost van der Mark, VP of Corp. Devel.
  • Ms. Neelu Atwal, Director of HR
  • Mr. Alfred D'Souza, Advisor

Who are some of BioSyent's key competitors?

What other stocks do shareholders of BioSyent own?

What is BioSyent's stock symbol?

BioSyent trades on the Canadian Venture Exchange (CVE) under the ticker symbol "RX."

How do I buy shares of BioSyent?

Shares of RX and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is BioSyent's stock price today?

One share of RX stock can currently be purchased for approximately C$7.75.

How much money does BioSyent make?

BioSyent has a market capitalization of C$98.29 million and generates C$23.69 million in revenue each year.

What is BioSyent's official website?

The official website for BioSyent is

Where are BioSyent's headquarters?

BioSyent is headquartered at 170 Attwell Dr Suite 520, ETOBICOKE, ON M9W 5Z5, Canada.

How can I contact BioSyent?

BioSyent's mailing address is 170 Attwell Dr Suite 520, ETOBICOKE, ON M9W 5Z5, Canada. The company can be reached via phone at +1-905-2060013.

This page was last updated on 8/1/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.